KRKA Wins Appeal, Court Lifts Ban on Generic Clopidogrel in Serbia

The Higher Commercial Court in Belgrade, Serbia has allowed KRKA’s appeal against the recent decision of the Commercial Court in Novi Sad, Serbia that granted the motion by Sanofi-Aventis for temporary injunction against the sales of generic Zyllt (clopidogrel hydrogen sulphate salt). Earlier on October 27, 2006 KRKA received adverse decision from Commercial Court which allowed Sanofi’s motion for temporary injunction due to alleged patent infringement protecting the clopidogrel and prohibiting import and sales activities in Serbia. However, KRKA subsequently appealed the decision for temporary injunction claiming that legal conditions for temporary injunction are still not fulfilled.